Home Newsfeeds Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Wolfe Research analyst Alex Zukin maintains DocuSign (NASDAQ:DOCU) with a Underperform and raises the price target from $50 to $53.

byBenzinga Newsdesk

September 12, 2022

1 minute read

Wolfe Research analyst Alex Zukin maintains DocuSign (NASDAQ:DOCU) with a Underperform and raises the price target from $50 to $53.

Cardano Is Now Listed On Robinhood: What You Need To Know

By Jose Rodrigo Safdiye

September 1, 10:53 AM

Robinhood (NASDAQ: HOOD) announced the listing of Cardano (CRYPTO: ADA) to its platform Thursday.

$ADA

BioAtla Presented Phase 2 Clinical Trial Data At The IASLC 2023 North America Conference On Lung Cancer And Virtual KOL Event

By Benzinga Newsdesk

December 5, 9:07 AM

Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints BA3011 is a

BCAB

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities And Anticipated 2024 Key Milestones

By Benzinga Newsdesk

January 4, 9:03 AM

Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM-rich allogeneic CAR-T to offer a differentiated and compelling efficacy, safety, and

PSTX

Alibaba, Meituan, Nio Jump: Hang Seng Looks Past Weak China Factory Data To Focus On Fed Policy

By Bhavik Nair

October 31, 12:05 AM

Hong Kong shares opened in the green on Monday, with the benchmark Hang Seng rising 0.63%, as investors and traders shrugged off a contraction in China’s factory activity while focussing more on the possibility of the U.S.

BABA

Wolfe Research Maintains Underperform on DocuSign, Raises Price Target to $53

Related Posts

Cardano Is Now Listed On Robinhood: What You Need To Know

BioAtla Presented Phase 2 Clinical Trial Data At The IASLC 2023 North America Conference On Lung Cancer And Virtual KOL Event

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities And Anticipated 2024 Key Milestones

Alibaba, Meituan, Nio Jump: Hang Seng Looks Past Weak China Factory Data To Focus On Fed Policy